151 related articles for article (PubMed ID: 37229797)
1. Targeted and untargeted urinary metabolic profiling of bladder cancer.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nieczaj A; Nizioł J
J Pharm Biomed Anal; 2023 Sep; 233():115473. PubMed ID: 37229797
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profiling of human bladder tissue extracts.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Krupa Z; Nizioł J
Metabolomics; 2024 Jan; 20(1):14. PubMed ID: 38267657
[TBL] [Abstract][Full Text] [Related]
3. Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Krupa Z; Ruman T
J Pharm Biomed Anal; 2024 Mar; 240():115966. PubMed ID: 38217999
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic and elemental profiling of blood serum in bladder cancer.
Ossoliński K; Ruman T; Copié V; Tripet BP; Nogueira LB; Nogueira KOPC; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nizioł J
J Pharm Anal; 2022 Dec; 12(6):889-900. PubMed ID: 36605581
[TBL] [Abstract][Full Text] [Related]
5. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
6. Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based serum metabolomics of kidney cancer.
Nizioł J; Ossoliński K; Tripet BP; Copié V; Arendowski A; Ruman T
Anal Bioanal Chem; 2020 Sep; 412(23):5827-5841. PubMed ID: 32661677
[TBL] [Abstract][Full Text] [Related]
7. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
8. Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Nieczaj A; Ruman T
Sci Rep; 2023 Jun; 13(1):9802. PubMed ID: 37328580
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
10. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
12. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
13. Monoisotopic silver nanoparticles-based mass spectrometry imaging of human bladder cancer tissue: Biomarker discovery.
Ossoliński K; Ruman T; Ossoliński T; Ossolińska A; Arendowski A; Kołodziej A; Płaza-Altamer A; Nizioł J
Adv Med Sci; 2023 Mar; 68(1):38-45. PubMed ID: 36566601
[TBL] [Abstract][Full Text] [Related]
14. Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers.
Chen YT; Huang HC; Hsieh YJ; Fu SH; Li L; Chen CL; Chu LJ; Yu JS
J Food Drug Anal; 2019 Apr; 27(2):460-474. PubMed ID: 30987717
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
16. Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Ruman T
Sci Rep; 2022 Sep; 12(1):15156. PubMed ID: 36071106
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
18. An integrative approach based on GC-qMS and NMR metabolomics data as a comprehensive strategy to search potential breast cancer biomarkers.
Silva CL; Perestrelo R; Capelinha F; Tomás H; Câmara JS
Metabolomics; 2021 Aug; 17(8):72. PubMed ID: 34389918
[TBL] [Abstract][Full Text] [Related]
19. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach.
Alberice JV; Amaral AF; Armitage EG; Lorente JA; Algaba F; Carrilho E; Márquez M; García A; Malats N; Barbas C
J Chromatogr A; 2013 Nov; 1318():163-70. PubMed ID: 24139504
[TBL] [Abstract][Full Text] [Related]
20. Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based metabolome profiling of urine samples from kidney cancer patients.
Nizioł J; Ossoliński K; Tripet BP; Copié V; Arendowski A; Ruman T
J Pharm Biomed Anal; 2021 Jan; 193():113752. PubMed ID: 33197834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
